Last updated date
ABOUT THIS STUDY
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with progressive metastatic transitional cell cancer of the urothelium.
Memorial Sloan-Kettering Cancer Center
New York, New York, 10021, United States
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Females and Males
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral CancerSunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
- New York, New York